While legalizing marijuana is in limbo, FDA clears a PTSD study that could boost cannabis stocks over time

The move marks a rare action by the FDA to sanction a study on cannabis despite the plant’s current Schedule I classification under federal law as a drug with no therapeutic use, in the same category as heroin and LSD.